Drugs / ABR2
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07593404 | May 2026 → Jan 2027 expected | dry eye syndrome | Pleryon Therapeutics (Hangzhou) Limited | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABR2 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07593404 ↗ |